Abstract 11348 – Embargoed until 8 a.m. PT /11 a.m. ET
November 05, 2012
This news release is featured in a news conference at 8 a.m. PT on Monday, Nov. 5, 2012.
- A new probiotic lowered LDL “bad” cholesterol and total cholesterol in patients with high cholesterol.
- The probiotic reduced molecules known as cholesterol ester saturated fatty acids, which have been tied to dangerous plaque buildup in the arteries.
American Heart Association Meeting Report:
LOS ANGELES, Nov. 5, 2012 — Two daily doses of a probiotic lowered key cholesterol-bearing molecules in the blood as well as “bad” and total cholesterol, in a study presented at the American Heart Association’s Scientific Sessions 2012.
Probiotics are live microorganisms (naturally occurring bacteria in the gut) thought to have beneficial effects; common sources are yogurt or dietary supplements.
In previous studies, a formulation of the bacteria, known as Lactobacillus reuteri NCIMB 30242, has lowered blood levels of LDL or “bad” cholesterol.
Such treatments are drawing increasing medical attention as researchers unravel how supplementing gut bacteria (microbiome) with probiotics can play a role in health and certain chronic diseases such as heart disease, said Mitchell L. Jones, M.D., Ph.D., lead author of the study and a research assistant in the Faculty of Medicine at McGill University in Montreal.
Researchers investigated whether the same probiotic could lower LDL and reduce blood levels of cholesterol esters — molecules of cholesterol attached to fatty acids, a combination that accounts for most total blood cholesterol and has been tied to cardiovascular disease risk.
Researchers tracked cholesterol esters bound to saturated fat, which have been linked to dangerous arterial plaque buildup and occur at higher levels in coronary artery disease patients.
The study involved 127 adult patients with high cholesterol. About half the participants took L. reuteri NCIMB 30242 twice a day, while the rest were given placebo capsules.
Those taking the probiotic had LDL levels 11.6 percent lower than those on placebo after nine weeks. Furthermore, cholesterol esters were reduced by 6.3 percent and cholesterol ester saturated fatty acids by 8.8 percent, compared with the placebo group.
For the first time, research shows that the probiotic formulation can reduce cholesterol esters “and in particular reduce the cholesterol esters associated with ‘bad’ saturated fatty acids in the blood,” said Jones, co-founder and chief science officer of Micropharma, the company that formulated the probiotic.
Furthermore, people taking the probiotic had total cholesterol reduced by 9.1 percent. HDL “good” cholesterol and blood triglycerides, a dangerous form of fat in the blood, were unchanged.
Scientists have proposed that Lactobacillus bacteria alone may impact cholesterol levels in several ways, including breaking apart molecules known as bile salts. L. reuteri NCIMB 30242 was fermented and formulated to optimize its effect on cholesterol and bile salts.
Based on correlations between LDL reduction and bile measurements in the gut, the study results suggest the probiotic broke up bile salts, leading to reduced cholesterol absorption in the gut and less LDL.
The probiotic worked at doses of just 200 milligrams a day, far lower than those for soluble fiber or other natural products used to reduce cholesterol.
“Most dietary cholesterol management products require consumption between 2 to 25 grams a day,” Jones said.
Patients appear to tolerate the probiotic well and the probiotic strain L. reuteri has a long history of safe use, he said.
Because of the small number of patients involved in the study, researchers aren’t sure if the impact of the probiotic differs between men and women or among ethnic groups.
Co-authors are Christopher J. Martoni, Ph.D. and Satya Prakash, Ph.D.
Micropharma funded the study and owns intellectual property rights for the formulation, which is expected to be on the U.S. market next year.
Follow news from the American Heart Association’s Scientific Sessions 2012 via Twitter: @HeartNews .
Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding .
Note: Actual presentation is at 4:45 p.m. PT/ 7:45 p.m. ET, Monday, Nov. 5, 2012 in Room 503.
All downloadable video/audio interviews, B-roll, animation and images related to this news release are on the right column of the release link at http://newsroom.heart.org/pr/aha/_prv-daily-doses-of-a-new-probiotic-239562.aspx.
Video clips with researchers/authors of studies will be added to the release links after embargo.
For Media Inquiries:
AHA News Media in Dallas: (214) 706-1173
AHA News Media Office, Nov. 3-7
at the Los Angeles Convention Center: (213) 743-6205
For Public Inquiries: (800) AHA-USA1 (242-8721)
Categories: Disease and Conditions, Missed - Medical Breakthroughs